$13.25
+1.13 (+9.32%)
Open$12.24
Previous Close$12.12
Day High$13.30
Day Low$12.24
52W High$55.89
52W Low$5.20
Volume—
Avg Volume113.9K
Market Cap195.70M
P/E Ratio—
EPS$-10.00
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
-69.5% upside
Current
$13.25
$13.25
Target
$4.04
$4.04
$2.50
$4.04 avg
$4.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.05M | 13.07M | 16.40M |
| Net Income | -184,339,724 | -215,798,324 | -3,544,265 |
| Profit Margin | -1,834.5% | -1,742.8% | -21.6% |
| EBITDA | -184,834,522 | -228,398,537 | -3,398,004 |
| Free Cash Flow | — | — | -3,167,900 |
| Rev Growth | -23.1% | -23.1% | +19.8% |
| Debt/Equity | — | — | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |